| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2023 | 17.6% | Barclays | $20 → $15 | Maintains | Overweight |
| 08/04/2023 | 72.48% | RBC Capital | $18 → $22 | Maintains | Outperform |
| 08/04/2023 | 80.32% | Keybanc | $24 → $23 | Maintains | Overweight |
| 06/26/2023 | 88.16% | Keybanc | → $24 | Upgrades | Sector Weight → Overweight |
| 06/22/2023 | — | Keybanc | Maintains | Sector Weight | |
| 05/04/2023 | 41.12% | RBC Capital | $19 → $18 | Maintains | Outperform |
| 05/04/2023 | 56.8% | Barclays | $21 → $20 | Maintains | Overweight |
| 04/04/2023 | 64.64% | Barclays | $22 → $21 | Maintains | Overweight |
| 03/01/2023 | 48.96% | RBC Capital | $8 → $19 | Maintains | Outperform |
| 01/23/2023 | 41.12% | JP Morgan | $6 → $18 | Upgrades | Underweight → Neutral |
| 01/11/2023 | 72.48% | Barclays | $6 → $22 | Upgrades | Underweight → Overweight |
| 01/11/2023 | 96% | Wolfe Research | → $25 | Upgrades | Peer Perform → Outperform |
| 11/23/2022 | -37.28% | Goldman Sachs | $9 → $8 | Maintains | Neutral |
| 11/16/2022 | -52.96% | Barclays | $7 → $6 | Downgrades | Equal-Weight → Underweight |
| 11/15/2022 | -52.96% | Barclays | $7 → $6 | Downgrades | Equal-Weight → Underweight |
| 11/03/2022 | -52.96% | JP Morgan | $9 → $6 | Maintains | Underweight |
| 11/03/2022 | -37.28% | RBC Capital | $25 → $8 | Maintains | Outperform |
| 10/06/2022 | -37.28% | Barclays | $22 → $8 | Maintains | Equal-Weight |
| 10/05/2022 | -29.44% | Citigroup | → $9 | Downgrades | Buy → Neutral |
| 09/26/2022 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 09/21/2022 | -29.44% | JP Morgan | $26 → $9 | Downgrades | Overweight → Underweight |
| 09/20/2022 | -29.44% | Goldman Sachs | $23 → $9 | Downgrades | Buy → Neutral |
| 07/13/2022 | 72.48% | Barclays | $24 → $22 | Maintains | Equal-Weight |
| 06/09/2022 | 103.84% | Wolfe Research | → $26 | Downgrades | Outperform → Peer Perform |
| 04/06/2022 | 103.84% | Wolfe Research | → $26 | Initiates Coverage On | → Outperform |
| 03/21/2022 | 111.68% | Goldman Sachs | $31 → $27 | Maintains | Buy |
| 03/03/2022 | 72.48% | Jefferies | $34 → $22 | Downgrades | Buy → Hold |
| 03/02/2022 | 119.52% | Credit Suisse | $31 → $28 | Maintains | Outperform |
| 03/02/2022 | 88.16% | Barclays | → $24 | Downgrades | Overweight → Equal-Weight |
| 03/02/2022 | 135.2% | Keybanc | $33 → $30 | Maintains | Overweight |
| 08/13/2021 | 150.88% | Barclays | $30 → $32 | Maintains | Overweight |
| 07/13/2021 | 135.2% | Barclays | $29 → $30 | Maintains | Overweight |
| 03/10/2021 | 158.72% | Keybanc | $31 → $33 | Maintains | Overweight |
| 03/03/2021 | 174.4% | Barclays | → $35 | Initiates Coverage On | → Overweight |
| 01/14/2021 | 143.04% | Baird | → $31 | Initiates Coverage On | → Outperform |
| 12/15/2020 | 143.04% | Keybanc | → $31 | Initiates Coverage On | → Overweight |
| 12/15/2020 | — | Credit Suisse | Initiates Coverage On | → Outperform | |
| 12/15/2020 | 166.56% | Goldman Sachs | → $34 | Initiates Coverage On | → Buy |
| 12/15/2020 | 162.64% | Jefferies | → $33.5 | Initiates Coverage On | → Buy |
| 12/15/2020 | 143.04% | RBC Capital | → $31 | Initiates Coverage On | → Outperform |
What is the target price for Sotera Health (SHC)?
The latest price target for Sotera Health (NASDAQ: SHC) was reported by Barclays on November 2, 2023. The analyst firm set a price target for $15.00 expecting SHC to rise to within 12 months (a possible 17.60% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sotera Health (SHC)?
The latest analyst rating for Sotera Health (NASDAQ: SHC) was provided by Barclays, and Sotera Health maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Sotera Health (SHC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sotera Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sotera Health was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.
Is the Analyst Rating Sotera Health (SHC) correct?
While ratings are subjective and will change, the latest Sotera Health (SHC) rating was a maintained with a price target of $20.00 to $15.00. The current price Sotera Health (SHC) is trading at is $12.76, which is out of the analyst's predicted range.